Loyalty Program Comparison: Allē vs Aspire vs Evolus Rewards

Allē operates on a quarterly volume-based rebate model tied to Botox and Juvéderm purchases. AbbVie has recently refreshed the program to include a quarterly Botox rebate for practices that hit growth thresholds—typically a percentage rebate on units purchased above a baseline or growth target. The structure rewards practices that increase spend year-over-year. Rebates are paid quarterly, not in real time, so cash flow timing matters. Allē also integrates with the Allē patient app, which drives patient loyalty and repeat bookings; this indirect benefit (higher patient retention and frequency) often exceeds the direct rebate value for many practices. Enrollment is free and typically requires minimal documentation beyond practice credentials and tax ID. The program's strength lies in its breadth—Botox, all Juvéderm SKUs, Volbella, and Vollure are eligible—and its integration with patient-facing loyalty (Allē points for patients). Weakness: rebate rates and thresholds are not publicly disclosed; you must negotiate directly with your AbbVie territory manager, and rates vary by region, practice size, and historical volume.

Galderma's Aspire program uses a tiered rebate structure based on annual spend across the Galderma aesthetic portfolio: Restylane (all forms), Dysport, Radiesse, and Sculptra. Unlike Allē, Aspire rebates are typically paid annually or semi-annually, not quarterly. Tier entry points are usually set at spend thresholds (e.g., $X in annual purchases unlocks Y% rebate). Galderma has expanded Aspire aggressively in recent years, particularly as GLP-1 weight-loss drug adoption has driven demand for facial rejuvenation (Galderma reported 25% growth in aesthetics sales in H1 2026, partly attributed to GLP-1 patient volume). Aspire's advantage is portfolio breadth—Dysport, Restylane, and biostimulators like Radiesse and Sculptra are all eligible—and Galderma's strong market position in fillers. The program also offers practice support tools and co-marketing resources. Weakness: rebate rates and tier thresholds are negotiated; transparency is lower than some competitors, and payout frequency (annual vs. quarterly) can create cash-flow drag compared to Allē.

Evolus Rewards is the simplest of the three: a straightforward rebate on Jeuveau (prabotulinumtoxinA) purchases, typically structured as a percentage rebate on units sold. The program does not use complex tiering; instead, rebates are usually calculated on total Jeuveau volume at a fixed or slightly volume-adjusted rate. Payouts are typically quarterly or semi-annually. Evolus has posted three consecutive quarters of positive adjusted EBITDA (Q2 2026) and raised full-year guidance, signaling financial stability and commitment to the program. Jeuveau's clinical profile is identical to Botox and Dysport (all are botulinum toxin type A), so clinical choice is neutral. Evolus Rewards' strength is simplicity and predictability—no complex tiering math, no regional variation in rates, and transparent communication of rebate amounts. Weakness: the program is limited to Jeuveau only; practices that use Jeuveau as a secondary or tertiary toxin (rather than primary) will earn lower total rebates than Allē or Aspire practices that use multiple product lines.

Most practices want to know: can I enroll in multiple programs simultaneously? The answer is yes, with caveats. You can be enrolled in Allē, Aspire, and Evolus Rewards at the same time. However, each program's rebate applies only to that manufacturer's products. You cannot earn an Allē rebate on Dysport (Galderma) or Jeuveau (Evolus), and vice versa. The real optimization question is product mix allocation: if you use Botox 60% of the time, Dysport 30%, and Jeuveau 10%, your rebate dollars will skew toward whichever program offers the highest rate on your primary toxin. Some practices negotiate exclusive or near-exclusive purchasing commitments with one manufacturer in exchange for higher rebate rates; this is common at larger practices ($1M+ annual toxin spend). Before committing to exclusivity, model the math: a 2-point rebate bump on 80% of your toxin volume may outweigh a lower rebate on 100% of volume. Verify exclusivity terms in writing—some programs allow you to maintain a small allocation to a competing toxin without losing rebate tier status.

Concrete example: a practice with $300K annual Botox spend at $12 per unit (25 units/vial, 12 vials/month) earns rebates as follows. Allē (estimated 3–5% rebate on growth): if the practice grows 10% year-over-year, rebate on incremental $30K spend ≈ $900–$1,500 annually. Aspire (estimated 2–4% tiered rebate): on $300K spend at 3% tier ≈ $9,000 annually. Evolus Rewards (estimated 2–3% flat rebate): on $300K Jeuveau spend at 2.5% ≈ $7,500 annually. Note: these are illustrative; actual rates depend on negotiation, region, and program terms. The key insight: rebate dollars are real margin, not marketing spend. A $9,000 annual rebate on $300K spend is a 3-point margin lift. For a practice with 40% gross margin on toxin, this moves the needle. Also factor in patient loyalty indirect benefit: Allē's patient app can drive 5–10% higher patient retention and booking frequency, which may be worth more than the direct rebate. Conversely, Aspire and Evolus Rewards offer less patient-facing integration, so their value is primarily direct rebate.

Choose your primary program based on your product mix and practice size. For practices with heavy Botox/Juvéderm use: Allē is typically optimal, especially if you value patient loyalty integration and can hit growth thresholds. For practices with balanced Dysport/Restylane/Radiesse portfolios: Aspire offers broader portfolio coverage and strong rebate rates on filler volume. For practices using Jeuveau as primary toxin or seeking simplicity: Evolus Rewards eliminates tiering complexity and offers transparent, predictable rebates. Enrollment is free and typically takes 1–2 weeks (verify credentials, tax ID, practice license). Once enrolled, you'll receive a dedicated account manager or online portal to track purchases and rebate accrual. Request a rebate rate sheet from your territory manager before enrolling; rates vary by region and are negotiable, especially for practices with $500K+ annual spend. Do not assume published rates apply to your practice—ask for your specific tier and rate. Finally, audit your rebate payouts quarterly; errors in unit counting or tier assignment are common, and catching them early prevents months of lost rebate.